Abstract
Post-Transplant Lymphoproliferative Disorder (PTLD) is a life-limiting transplant complication with serious implications. It is most commonly encountered in the first year after transplant and is related to the degree of immunosuppressive therapy and donor/recipient EBV serostatus. Diagnostic workup involves a clinical review of symptoms, as well as laboratory and radiological testing. Diagnosis is confirmed by obtaining tissue biopsy and histopathological evaluation. A cornerstone of treatment involves reducing immunosuppression and PTLD directed therapy in consultation with hematological oncology. No EBV directed anti-viral treatment is currently the standard of care for prophylaxis or treatment of EBV viremia.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant. 1995;14(2):214–21.
McDonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant. 2008;8(5):984–9.
Caillard S, Lelong C, Pessione F, Moulin B. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French registry. Am J Transplant. 2006;6(11):2735–42.
Ali H, Soliman K, Daoud A, et al. Relationship between rabbit anti-thymocyte globulin and development of PTLD and its aggressive form in renal transplant population. Ren Fail. 2020;42(1):489–94.
Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, vol. 2. France: International agency for research on cancer Lyon; 2008.
Swinnen LJ, LeBlanc M, Grogan TM, et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation. 2008;86(2):215–22.
Adami J, Gäbel H, Lindelöf B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89(7):1221–7.
Leblond V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol. 1998;16(6):2052–9.
Caillard S, Porcher R, Provot F, et al. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. J Clin Oncol. 2013;31(10):1302–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Jan, M.Y., Sharfuddin, A.A. (2022). Post-Transplant Lymphoproliferative Disorder: Overview. In: Aziz, F., Parajuli, S. (eds) Complications in Kidney Transplantation. Springer, Cham. https://doi.org/10.1007/978-3-031-13569-9_47
Download citation
DOI: https://doi.org/10.1007/978-3-031-13569-9_47
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-13568-2
Online ISBN: 978-3-031-13569-9
eBook Packages: MedicineMedicine (R0)